You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞稱其第三劑疫苗可對奧密克戎起到中和作用
格隆匯 12-09 06:45
格隆匯12月9日丨週三,輝瑞-BioNTech實驗室測試顯示,接種第三劑新冠疫苗可以中和奧密克戎變異株,接種兩劑疫苗對其的中和效果明顯較差,但仍可預防嚴重疾病。此外輝瑞表示,公司將繼續研發一種針對奧密克戎變異株的疫苗,並預計在明年3月之前推出,以備需要進行適應。第三劑疫苗針對奧密克戎變異株的BNT162B2中和抗體滴度比兩劑疫苗的滴度增加25倍;確保儘可能多的人充分接種兩劑疫苗及加強劑仍然是預防新冠傳播的最佳行動方針。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account